Antisense & RNAi Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type ( RNA Interference,SiRNA,MiRNA,Antisense RNA ), By Application ( Oncology,Cardiovascular,Renal,Neurodegenerative,Respiratory,Genetic,Infectious Diseases ), Regional Insights and Forecast to 2035

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Antisense & RNAi Therapeutics Market Size 2019-2030
2.1.2 Antisense & RNAi Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Antisense & RNAi Therapeutics Segment by Type
2.2.1 RNA Interference
2.2.2 SiRNA
2.2.3 MiRNA
2.2.4 Antisense RNA
2.3 Antisense & RNAi Therapeutics Market Size by Type
2.3.1 Antisense & RNAi Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Antisense & RNAi Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Antisense & RNAi Therapeutics Segment by Application
2.4.1 Oncology
2.4.2 Cardiovascular
2.4.3 Renal
2.4.4 Neurodegenerative
2.4.5 Respiratory
2.4.6 Genetic
2.4.7 Infectious Diseases
2.5 Antisense & RNAi Therapeutics Market Size by Application
2.5.1 Antisense & RNAi Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Antisense & RNAi Therapeutics Market Size Market Share by Application (2019-2024)
3 Antisense & RNAi Therapeutics Market Size by Player
3.1 Antisense & RNAi Therapeutics Market Size Market Share by Players
3.1.1 Global Antisense & RNAi Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Antisense & RNAi Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Antisense & RNAi Therapeutics by Regions
4.1 Antisense & RNAi Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Antisense & RNAi Therapeutics Market Size Growth (2019-2024)
4.3 APAC Antisense & RNAi Therapeutics Market Size Growth (2019-2024)
4.4 Europe Antisense & RNAi Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Antisense & RNAi Therapeutics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Antisense & RNAi Therapeutics Market Size by Country (2019-2024)
5.2 Americas Antisense & RNAi Therapeutics Market Size by Type (2019-2024)
5.3 Americas Antisense & RNAi Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antisense & RNAi Therapeutics Market Size by Region (2019-2024)
6.2 APAC Antisense & RNAi Therapeutics Market Size by Type (2019-2024)
6.3 APAC Antisense & RNAi Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Antisense & RNAi Therapeutics by Country (2019-2024)
7.2 Europe Antisense & RNAi Therapeutics Market Size by Type (2019-2024)
7.3 Europe Antisense & RNAi Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Antisense & RNAi Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Antisense & RNAi Therapeutics Market Forecast
10.1 Global Antisense & RNAi Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Antisense & RNAi Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Antisense & RNAi Therapeutics Forecast
10.1.3 APAC Antisense & RNAi Therapeutics Forecast
10.1.4 Europe Antisense & RNAi Therapeutics Forecast
10.1.5 Middle East & Africa Antisense & RNAi Therapeutics Forecast
10.2 Americas Antisense & RNAi Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Antisense & RNAi Therapeutics Market Forecast
10.2.2 Canada Antisense & RNAi Therapeutics Market Forecast
10.2.3 Mexico Antisense & RNAi Therapeutics Market Forecast
10.2.4 Brazil Antisense & RNAi Therapeutics Market Forecast
10.3 APAC Antisense & RNAi Therapeutics Forecast by Region (2025-2030)
10.3.1 China Antisense & RNAi Therapeutics Market Forecast
10.3.2 Japan Antisense & RNAi Therapeutics Market Forecast
10.3.3 Korea Antisense & RNAi Therapeutics Market Forecast
10.3.4 Southeast Asia Antisense & RNAi Therapeutics Market Forecast
10.3.5 India Antisense & RNAi Therapeutics Market Forecast
10.3.6 Australia Antisense & RNAi Therapeutics Market Forecast
10.4 Europe Antisense & RNAi Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Antisense & RNAi Therapeutics Market Forecast
10.4.2 France Antisense & RNAi Therapeutics Market Forecast
10.4.3 UK Antisense & RNAi Therapeutics Market Forecast
10.4.4 Italy Antisense & RNAi Therapeutics Market Forecast
10.4.5 Russia Antisense & RNAi Therapeutics Market Forecast
10.5 Middle East & Africa Antisense & RNAi Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Antisense & RNAi Therapeutics Market Forecast
10.5.2 South Africa Antisense & RNAi Therapeutics Market Forecast
10.5.3 Israel Antisense & RNAi Therapeutics Market Forecast
10.5.4 Turkey Antisense & RNAi Therapeutics Market Forecast
10.5.5 GCC Countries Antisense & RNAi Therapeutics Market Forecast
10.6 Global Antisense & RNAi Therapeutics Forecast by Type (2025-2030)
10.7 Global Antisense & RNAi Therapeutics Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Glaxo Smith Kline
11.1.1 Glaxo Smith Kline Company Information
11.1.2 Glaxo Smith Kline Antisense & RNAi Therapeutics Product Offered
11.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Glaxo Smith Kline Main Business Overview
11.1.5 Glaxo Smith Kline Latest Developments
11.2 Sanofi Aventis / Genzyme
11.2.1 Sanofi Aventis / Genzyme Company Information
11.2.2 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product Offered
11.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Sanofi Aventis / Genzyme Main Business Overview
11.2.5 Sanofi Aventis / Genzyme Latest Developments
11.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
11.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Information
11.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Main Business Overview
11.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Latest Developments
11.4 Arbutus Biopharma Ltd.
11.4.1 Arbutus Biopharma Ltd. Company Information
11.4.2 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product Offered
11.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Arbutus Biopharma Ltd. Main Business Overview
11.4.5 Arbutus Biopharma Ltd. Latest Developments
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Information
11.5.2 Silence Therapeutics Antisense & RNAi Therapeutics Product Offered
11.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Silence Therapeutics Main Business Overview
11.5.5 Silence Therapeutics Latest Developments
11.6 Bio-Path Holdings Inc.
11.6.1 Bio-Path Holdings Inc. Company Information
11.6.2 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product Offered
11.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Bio-Path Holdings Inc. Main Business Overview
11.6.5 Bio-Path Holdings Inc. Latest Developments
11.7 Calando Pharmaceuticals
11.7.1 Calando Pharmaceuticals Company Information
11.7.2 Calando Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Calando Pharmaceuticals Main Business Overview
11.7.5 Calando Pharmaceuticals Latest Developments
11.8 ICo Therapeutics
11.8.1 ICo Therapeutics Company Information
11.8.2 ICo Therapeutics Antisense & RNAi Therapeutics Product Offered
11.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 ICo Therapeutics Main Business Overview
11.8.5 ICo Therapeutics Latest Developments
11.9 Quark Pharmaceuticals
11.9.1 Quark Pharmaceuticals Company Information
11.9.2 Quark Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Quark Pharmaceuticals Main Business Overview
11.9.5 Quark Pharmaceuticals Latest Developments
11.10 Rexhan Pharmaceuticals
11.10.1 Rexhan Pharmaceuticals Company Information
11.10.2 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Rexhan Pharmaceuticals Main Business Overview
11.10.5 Rexhan Pharmaceuticals Latest Developments
11.11 Biomarin/Prosensa
11.11.1 Biomarin/Prosensa Company Information
11.11.2 Biomarin/Prosensa Antisense & RNAi Therapeutics Product Offered
11.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Biomarin/Prosensa Main Business Overview
11.11.5 Biomarin/Prosensa Latest Developments
11.12 Regulus Therapeutics
11.12.1 Regulus Therapeutics Company Information
11.12.2 Regulus Therapeutics Antisense & RNAi Therapeutics Product Offered
11.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Regulus Therapeutics Main Business Overview
11.12.5 Regulus Therapeutics Latest Developments
11.13 Rxi Pharmaceuticals
11.13.1 Rxi Pharmaceuticals Company Information
11.13.2 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Rxi Pharmaceuticals Main Business Overview
11.13.5 Rxi Pharmaceuticals Latest Developments
11.14 Silenseed
11.14.1 Silenseed Company Information
11.14.2 Silenseed Antisense & RNAi Therapeutics Product Offered
11.14.3 Silenseed Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Silenseed Main Business Overview
11.14.5 Silenseed Latest Developments
11.15 Dicerna Pharmaceuticals
11.15.1 Dicerna Pharmaceuticals Company Information
11.15.2 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Dicerna Pharmaceuticals Main Business Overview
11.15.5 Dicerna Pharmaceuticals Latest Developments
11.16 Sirnaomics Inc.
11.16.1 Sirnaomics Inc. Company Information
11.16.2 Sirnaomics Inc. Antisense & RNAi Therapeutics Product Offered
11.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Sirnaomics Inc. Main Business Overview
11.16.5 Sirnaomics Inc. Latest Developments
12 Research Findings and Conclusion